Universal Library of Medical and Health Sciences Review Article

ISSN: 3064-6545 | Volume 2, Issue 4

Open Access | PP: 15-19

DOI: https://doi.org/10.70315/uloap.ulmhs.2024.0204002

Malignant Diseases Associated with COVID-19 Infection

Yongxin Zhang[1,2]*, Ying Wang[1,3]

[1]Zyxell Inc. Carrollton, Texas, USA.

[2]ZYX Biotech Company, Carrollton, Texas, USA.

[3]Quest Diagnostics, Lewisville, Texas, USA.

Abstract

The COVID-19 pandemic has had significant implications for patients with malignant diseases, revealing complex interactions between viral infection and cancer. This review explores the association of COVID-19 infection with various malignant diseases, including hematological malignancies and solid tumors. Potential mechanisms underlying this association include immune dysregulation, chronic inflammation, and alterations in the tumor microenvironment. Additionally, the pandemic has disrupted cancer care, leading to delays in diagnosis and treatment while increasing the vulnerability of cancer patients to severe COVID-19 outcomes. The review emphasizes the need for enhanced cancer care protocols, ongoing research into the long-term effects of COVID-19 on cancer progression, and support for the psychosocial needs of patients. By addressing these challenges, the healthcare community can improve patient outcomes and develop effective strategies for managing malignant diseases in the context of a global pandemic.

Keywords: *Malignant Diseases; Cancer; COVID-19; Infection; Immunity.*

INTRODUCTION

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has had a profound impact on global health, affecting millions of individuals worldwide. As the pandemic has progressed, evidence has emerged suggesting an association between COVID-19 infection and the development [1-3] or exacerbation of malignant diseases. Malignant diseases, which include various types of cancers, are known to interact with viral infections, influencing disease progression and patient outcomes. This review aims to explore the types of malignant diseases associated with COVID-19 infection, potential mechanisms behind this association, and the broader implications for cancer patients during the pandemic.

OVERVIEW OF MALIGNANT DISEASES ASSOCIATED WITH COVID-19

Research indicates that individuals infected with COVID-19 may experience an increased risk of developing certain malignant diseases [4-7], particularly hematological malignancies such as lymphoma and leukemia [6, 7], as well as complications related to solid tumors [3- 5]. Studies have suggested that COVID-19 may not only exacerbate pre-existing malignancies but also contribute to the emergence of new cases in vulnerable populations [4-7].

The relationship between COVID-19 and malignant diseases is complex and multifactorial. Factors such as immune suppression, inflammation, and the impact of the viral infection on the tumor microenvironment may all play significant roles [8-11]. For instance, patients with compromised immune systems—such as those undergoing cancer treatments—may face heightened risks, as their bodies are less able to mount an effective response to the virus and its associated complications.

MECHANISMS OF ASSOCIATION

The interplay between COVID-19 infection and malignant diseases can be attributed to several potential mechanisms, which include immune dysregulation, chronic inflammation, and alterations in the tumor microenvironment.

Immune Dysregulation

COVID-19 has been shown to cause significant dysregulation of the immune system, leading to an exaggerated inflammatory response known as a cytokine storm [12, 13]. This immune response can be particularly detrimental for cancer patients, as it may compromise their already weakened immune systems, impairing their ability to fight both the viral infection and malignancies. Additionally, the virus can lead to lymphopenia (a decrease in lymphocytes) [14, 15], which is crucial for immune surveillance against tumors. Reduced lymphocyte counts can hinder the body's capacity to detect and eliminate cancer cells, potentially leading to an increased risk of malignancy.

Chronic Inflammation

Chronic inflammation is a well-known risk factor for cancer development. COVID-19 can induce a state of prolonged inflammation, especially in long COVID [16, 17], which

may contribute to the pathogenesis of certain cancers. For instance, the inflammatory cytokines released during COVID-19 can promote tumor growth and progression in individuals with pre-existing malignancies. Furthermore, the presence of the virus in the body can create an environment conducive to tumorigenesis through the activation of oncogenic signaling pathways.

Alterations in Tumor Microenvironment

The tumor microenvironment plays a critical role in cancer progression and response to treatment. COVID-19 infection can lead to changes in the tumor microenvironment [18, 19], such as increased fibrosis, vascular leakage, and altered immune cell infiltration. These changes may affect tumor behavior and treatment responses, making malignancies more aggressive or resistant to therapy. Additionally, the direct effects of the virus on tumor cells, as well as indirect effects through the immune response, could further complicate the clinical picture for cancer patients [20, 21].

IMPACT ON CANCER PATIENTS DURING THE PANDEMIC

The COVID-19 pandemic has had profound implications for cancer patients, affecting their treatment, diagnosis, and overall health outcomes. With healthcare systems strained under the weight of the pandemic, many cancer patients faced disruptions in their care.

Disruption of Cancer Care

During the early stages of the pandemic, many elective procedures, routine screenings, and non-urgent cancer treatments were postponed or canceled. This disruption has led to delayed diagnoses and treatment initiation for numerous patients. The postponement of surgeries and chemotherapy could potentially lead to worsened prognoses, particularly for aggressive cancers where timely intervention is critical [22, 23].

Increased Vulnerability

Cancer patients are often immunocompromised due to the malignancy itself or the effects of treatment modalities such as chemotherapy, radiation, and immunotherapy. This immunocompromised state heightens their vulnerability to COVID-19, increasing the risk of severe illness and mortality [24, 25]. Studies have shown that cancer patients infected with COVID-19 have worse outcomes compared to non-cancer patients, including higher rates of hospitalization, intensive care unit (ICU) admission, and mortality [26-28].

Psychosocial Impact

The pandemic has also taken a toll on the mental health of cancer patients [29, 30]. The fear of contracting COVID-19, combined with the isolation resulting from lockdowns and social distancing measures, has contributed to increased anxiety, depression, and feelings of helplessness among this population. Access to support networks and mental health services has been limited, exacerbating the psychosocial burden faced by cancer patients during the pandemic.

LONG-TERM IMPLICATIONS

As the world continues to navigate the effects of COVID-19, the long-term implications for cancer care remain a concern. Ongoing research is essential to understand the potential late effects of COVID-19 on cancer patients, including the risk of recurrence, the development of new malignancies, and the impact on overall survival. Continuous monitoring and adapting treatment protocols will be crucial to mitigate these risks and ensure optimal care for cancer patients moving forward.

CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS

The relationship between COVID-19 and malignant diseases underscores the urgent need for adaptations in cancer care and research priorities. Understanding the risks associated with COVID-19 infection for cancer patients is crucial for optimizing clinical management and improving patient outcomes.

Enhancing Cancer Care Protocols

Healthcare providers must adapt cancer care protocols to account for the potential complications associated with COVID-19. This includes ensuring timely vaccinations against COVID-19 for cancer patients, as vaccination can significantly reduce the risk of severe illness [31, 32]. Additionally, cancer treatment regimens may require adjustments to minimize the risk of infection during periods of high community transmission. For example, clinicians might consider alternative treatment strategies, such as remote consultations for routine follow-ups, to limit patient exposure in healthcare settings.

Ongoing Surveillance and Research

Longitudinal studies are needed to monitor the long-term effects of COVID-19 on cancer patients, including the risk of recurrence and the development of new malignancies. Research should focus on understanding the biological mechanisms linking COVID-19 infection to cancer progression and the potential impacts on immune response in cancer patients. This knowledge will be vital for developing targeted interventions to mitigate these risks.

Addressing Psychosocial Needs

The pandemic has highlighted the importance of addressing the psychosocial needs of cancer patients. Healthcare providers should implement strategies to provide psychological support, including counseling and support groups, to help patients cope with the emotional toll of living with cancer during a pandemic. Additionally, enhancing communication with patients about the risks of COVID-19 and the benefits of vaccination can help alleviate anxiety and improve treatment adherence.

Future Research Directions

Looking ahead, prioritizing research at the intersection of viral infections and cancer biology is crucial. A deeper investigation into how COVID-19 impacts the tumor microenvironment, promotes immune evasion [33], activates cancer stem cells [34], and contributes to treatment resistance will provide valuable insights for cancer therapy development. Collaborative efforts among oncologists, virologists, and immunologists are essential to fostering innovative strategies for understanding and addressing the effects of COVID-19 on malignancies. Moreover, further research is needed to explore effective prevention strategies against the progression to cancer in individuals infected with COVID-19, including assessing the potential role of vaccination in reducing post-COVID cancer risk.

CONCLUSION

The COVID-19 pandemic has unveiled significant challenges for cancer patients, revealing an intricate relationship between viral infection and malignant diseases. Evidence indicates that COVID-19 can exacerbate pre-existing malignancies and may be associated with the development of new cancers, particularly in immunocompromised individuals. The pandemic has disrupted cancer care, leading to delays in diagnosis and treatment while heightening the vulnerability of cancer patients to severe COVID-19 outcomes.

As we move forward, it is crucial to prioritize the adaptation of cancer care protocols to ensure the safety and well-being of patients. Vaccination efforts must be emphasized, and ongoing surveillance is necessary to understand the long-term implications of COVID-19 on cancer progression and patient outcomes. By addressing the psychosocial needs of patients and fostering research collaborations, the healthcare community can better navigate the complexities of managing malignant diseases in the context of a global pandemic. Ultimately, understanding the association between COVID-19 and malignancies will be key to improving clinical strategies and enhancing patient care in the post-pandemic world.

REFERENCES

1. Jahankhani K, Ahangari F, Adcock IM, Mortaz E. Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent? Biochimie. 2023 Oct;213:130-138. doi: 10.1016/j.biochi.2023.05.014. Epub 2023 May 23. PMID: 37230238; PMCID: PMC10202899.
2. Ogarek N, Oboza P, Olszanecka-Glinianowicz M, Kocelak P. SARS-CoV-2 infection as a potential risk factor for the development of cancer. Front Mol Biosci. 2023 Sep 11;10:1260776. doi: 10.3389/fmolb.2023.1260776. PMID: 37753372; PMCID: PMC10518417.
3. Li J, Bai H, Qiao H, et al. Causaleffects of COVID-19 on cancer risk: a Mendelianrandomization study. J Med Virol. 2023;95:e28722.doi:10.1002/jmv.28722LI ET AL . 11 of 11
4. Jahankhani K, Ahangari F, Adcock IM, Mortaz E. Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent? Biochimie. 2023 Oct;213:130-138. doi: 10.1016/j.biochi.2023.05.014. Epub 2023 May 23. PMID: 37230238; PMCID: PMC10202899.
5. Shoumariyeh K, Biavasco F, Ihorst G, Rieg S, Nieters A, Kern WV, et al. Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer Med. 2020 Nov;9(22):8412-8422. doi: 10.1002/cam4.3460. Epub 2020 Sep 15. PMID: 32931637; PMCID: PMC7666742.
6. Bruno Almeida Costa, Kaiza Vilarinho da Luz, Sarah Emanuelle Viana Campos, Germison Silva Lopes, João Paulo de Vasconcelos Leitão, Fernando Barroso Duarte. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature.Hematology, Transfusion and Cell Therapy.2022; 44(1):26-31.
7. Ioannidou M, Tragiannidis A, Hatzipantelis E. Acute Leukemia in children after recent COVID-19 infection. Possible association? Hippokratia. 2021 Jan-Mar;25(1):47. PMID: 35221656; PMCID: PMC8877928.
8. Stainer A, Amati F, Suigo G, Simonetta E, Gramegna A, Voza A, Aliberti S. COVID-19 in Immunocompromised Patients: A Systematic Review. Semin Respir Crit Care Med. 2021 Dec;42(6):839-858. doi: 10.1055/s-0041-1740110. Epub 2021 Dec 16. PMID: 34918325.
9. Baek MS, Lee MT, Kim WY, Choi JC, Jung SY. COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea. PLoS One. 2021 Oct 1;16(10):e0257641. doi: 10.1371/journal.pone.0257641. PMID: 34597325; PMCID: PMC8486114.
10. Patel RH, Vanaparthy R, Greene JN. COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature. Cancer Control. 2021 Jan-Dec;28:10732748211044361. doi: 10.1177/10732748211044361. PMID: 34579537; PMCID: PMC8482717.
11. Connelly JA, Chong H, Esbenshade AJ, Frame D, Failing C, Secord E, Walkovich K. Impact of COVID-19 on Pediatric Immunocompromised Patients. Pediatr Clin North Am. 2021 Oct;68(5):1029-1054. doi: 10.1016/j.pcl.2021.05.007. Epub 2021 May 26. PMID: 34538297; PMCID: PMC8149202.
12. Montazersaheb, S., Hosseiniyan Khatibi, S.M., Hejazi, M.S. *et al.* COVID-19 infection: an overview on cytokine storm and related interventions. *Virol J* 19, 92 (2022). https://doi.org/10.1186/s12985-022-01814-1
13. Zanza, C.; Romenskaya, T.; Manetti, A.C.; Franceschi, F.; La Russa, R.; Bertozzi, G.; Maiese, A.; Savioli, G.; Volonnino, G.; Longhitano, Y. Cytokine Storm in COVID-19:

Immunopathogenesis and Therapy. *Medicina* 2022, *58*, 144. https://doi.org/10.3390/medicina58020144

14. Huang, I., Pranata, R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. *j intensive care* 8, 36 (2020). https://doi.org/10.1186/s40560-020-00453-4

15. Jafarzadeh A, Jafarzadeh S,Nozari P, Mokhtari P, Nemati M. Lymphopenia animportant immunological abnormality in patients withCOVID-19: Possible mechanisms. Scand J Immunol.2021;93:e12967. https://doi.org/10.1111/sji.12967

16. Al-Hakeim, H.K., Al-Rubaye, H.T., Al-Hadrawi, D.S. *et al.* Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. *Mol Psychiatry* 28, 564–578 (2023). https://doi.org/10.1038/s41380-022-01836-9

17. Kuchler, T., Günthner, R., Ribeiro, A. *et al.* Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation. *Angiogenesis* 26, 547–563 (2023). https://doi.org/10.1007/s10456-023-09885-6

18. Malkani, N., Rashid, M.U. SARS-COV-2 infection and lung tumor microenvironment. *Mol Biol Rep* 48, 1925–1934 (2021). https://doi.org/10.1007/s11033-021-06149-8

19. Ye C-H, Hsu W-L, Peng G-R, et al. Role of the Immune Microenvironment in SARS-CoV-2 Infection. *Cell Transplantation*. 2021;30. doi:10.1177/09636897211010632

20. Kasra Jahankhani, Fatemeh Ahangari, Ian M. Adcock, Esmaeil Mortaz. Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent? Biochimie 213:130-138. https://doi.org/10.1016/j.biochi.2023.05.014.

21. Geisslinger, F.; Vollmar, A.M.; Bartel, K. Cancer Patients Have a Higher Risk Regarding COVID-19–and Vice Versa? *Pharmaceuticals* 2020, *13*, 143. https://doi.org/10.3390/ph13070143

22. Abdul Rahman Jazieh et al. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. *JCO Glob Oncol* 6, 1428-1438(2020). DOI:10.1200/GO.20.00351

23. Al-Quteimat, Osama M. MSc, BCOP*; Amer, Amer Mustafa BSc, MSc†. The Impact of the COVID-19 Pandemic on Cancer Patients. American Journal of Clinical Oncology 43(6):p 452-455, June 2020. | DOI: 10.1097/COC.0000000000000712

24. Saloni Bhatia, Padmini Gokhale, Teesta Katte, Shreeshanthi Acharya, Avinash Arvind Rasalkar, et al. Assessing the Vulnerability of Cancer Patients for COVID-19. *ACS Omega* 2022 *7* (40), 35735-35742. DOI: 10.1021/acsomega.2c03764

25. Mengyuan Dai, Dianbo Liu, Miao Liu, Fuxiang Zhou, Guiling Li, Zhen Chen, et al. Mucci, Mauricio Santillana, Hongbing Cai; Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. *Cancer Discov* 1 June 2020; 10 (6): 783–791. https://doi.org/10.1158/2159-8290.CD-20-0422

26. Tang LV, Hu Y. Poor clinical outcomes for patients with cancer during the COVID-19 pandemic. Lancet Oncol. 2020 Jul;21(7):862-864. doi: 10.1016/S1470-2045(20)30311-9. Epub 2020 May 29. PMID: 32479788; PMCID: PMC7259901.

27. Gagandeep Brar et al. COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. JCO 38, 3914-3924(2020). DOI:10.1200/JCO.20.01580

28. Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol. 2022;8(1):69–78. doi:10.1001/jamaoncol.2021.5148

29. Edge, Rhiannon, et al. "Psychosocial impact of COVID-19 on cancer patients, survivors, and carers in Australia: a real-time assessment of cancer support services." Supportive Care in Cancer 29 (2021): 5463-5473.

30. Amaniera, Isabella, et al. Psychosocial impact of the COVID-19 pandemic on cancer patients, survivors and caregivers. Journal of Psychosocial Oncology 39.3 (2021): 485-492.

31. Seneviratne SL, Yasawardene P, Wijerathne W, Somawardana B. COVID-19 vaccination in cancer patients: a narrative review. Journal of International Medical Research. 2022;50(3). doi:10.1177/03000605221086155

32. Fendler, A., de Vries, E.G.E., GeurtsvanKessel, C.H. et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol 19, 385–401 (2022). https://doi.org/10.1038/s41571-022-00610-8

33. Yongxin Zhang, Ying Wang, William Decker, Zhenying Wang, and Monica Zimmerman. Adaptive Modulation of MHC Class I Expression and Immune Evasion to Cytotoxic Immunocytes in Cancer Cells. International Journal of Engineering and Applied Science 2017; 4(10):14.

34. Yongxin Zhang, Ying Wang, William Decker, Zhenying Wang, and Monica Zimmerman. Inhibition of Cancer Cell

Immune Evasion by Combined Application of Cytotoxic T-Lymphocytes and Natural Killer Cells. Journal of Translational Research 2018; 2 (1):1-8. http://www.alliedacademies.org/journal-translational-research/current-issue.php

35. Yongxin Zhang, Ying Wang, Zhenying Wang, Farhang Farhangfar and Monica Zimmerman. Improvement of cancer stem cell expansion with kinetic and static alternating culture system. Journal of Translational Research 2018;2(1): 2-7.

Citation: Yongxin Zhang, Ying Wang, "Malignant Diseases Associated with COVID-19 Infection", Universal Library of Medical and Health Sciences, 2024; 2(4): 15-19. DOI: https://doi.org/10.70315/uloap.ulmhs.2024.0204002.